Kang Xiao1,2, Fengxi Liu1,3, Juan Liu1, Jiwei Xu1, Qiuyun Wu1, Xiao Li1,3. 1. Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University, Shandong First Medical University, Jinan, China. 2. Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing, China. 3. Department of Clinical pharmacy, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China.
Abstract
WHAT IS KNOWN AND OBJECTIVE: Metformin has received increasing attention owing to its potential protective effect against cancer. We aimed to summarize evidence regarding the association between metformin and the risk or survival in lung cancer patients with type 2 diabetes. METHODS: We selected observational studies examining the association between exposure to metformin and the risk or survival in lung cancer. Available publications were searched in PubMed, Cochrane Library, ScienceDirect, Wiley and SpringerLink databases. Meta-analysis was performed with hazard ratios (HRs) and 95% confidence intervals (95% CIs) as effect measures for risk or survival in lung cancer. RESULTS: Eighteen studies (eight on lung cancer risk and ten on lung cancer survival) were included. Metformin treatment was associated with decreased lung cancer incidence (HR 0.78; 95% CI 0.70-0.86) and increased lung cancer survival (HR 0.65; 95% CI 0.55-0.77). In the subgroup analysis by ethnicity, a significant protective effect of metformin use on lung cancer risk was observed among Asian patients (HR 0.66; 95% CI 0.56-0.76), but not in European patients. On the other hand, the protective effect of metformin use on lung cancer survival was observed in both Asian (HR 0.57; 95% CI 0.49-0.66) and non-Asian (HR 0.79; 95% CI 0.71-0.88) patients. In the subgroup analysis by histology, a protective effect of metformin on lung cancer survival was observed in both non-small-cell lung cancer (HR 0.68; 95% CI 0.54-0.84) and small-cell lung cancer (HR 0.52; 95% CI 0.39-0.69). Funnel plot showed that no significant publication bias existed. CONCLUSIONS: Our findings demonstrate that metformin is significantly associated with a decreased risk and increased survival in lung cancer.
WHAT IS KNOWN AND OBJECTIVE:Metformin has received increasing attention owing to its potential protective effect against cancer. We aimed to summarize evidence regarding the association between metformin and the risk or survival in lung cancerpatients with type 2 diabetes. METHODS: We selected observational studies examining the association between exposure to metformin and the risk or survival in lung cancer. Available publications were searched in PubMed, Cochrane Library, ScienceDirect, Wiley and SpringerLink databases. Meta-analysis was performed with hazard ratios (HRs) and 95% confidence intervals (95% CIs) as effect measures for risk or survival in lung cancer. RESULTS: Eighteen studies (eight on lung cancer risk and ten on lung cancer survival) were included. Metformin treatment was associated with decreased lung cancer incidence (HR 0.78; 95% CI 0.70-0.86) and increased lung cancer survival (HR 0.65; 95% CI 0.55-0.77). In the subgroup analysis by ethnicity, a significant protective effect of metformin use on lung cancer risk was observed among Asian patients (HR 0.66; 95% CI 0.56-0.76), but not in European patients. On the other hand, the protective effect of metformin use on lung cancer survival was observed in both Asian (HR 0.57; 95% CI 0.49-0.66) and non-Asian (HR 0.79; 95% CI 0.71-0.88) patients. In the subgroup analysis by histology, a protective effect of metformin on lung cancer survival was observed in both non-small-cell lung cancer (HR 0.68; 95% CI 0.54-0.84) and small-cell lung cancer (HR 0.52; 95% CI 0.39-0.69). Funnel plot showed that no significant publication bias existed. CONCLUSIONS: Our findings demonstrate that metformin is significantly associated with a decreased risk and increased survival in lung cancer.
Authors: Amanda Leiter; Antonios Charokopos; Stacyann Bailey; Emily J Gallagher; Fred R Hirsch; Derek LeRoith; Juan P Wisnivesky Journal: Transl Lung Cancer Res Date: 2021-11
Authors: Eusebio Chiefari; Maria Mirabelli; Sandro La Vignera; Sinan Tanyolaç; Daniela Patrizia Foti; Antonio Aversa; Antonio Brunetti Journal: Int J Mol Sci Date: 2021-10-15 Impact factor: 5.923
Authors: Ameya S Kulkarni; Sandra Aleksic; David M Berger; Felipe Sierra; George A Kuchel; Nir Barzilai Journal: Aging Cell Date: 2022-03-27 Impact factor: 9.304